Genomic Medicine Institute

The Genomic Medicine Institute (GMI) serves as the expert base for the principles and practice of genomic medicine, including genetics and genomics research, clinical care, and outreach and education directed at genomics-based personalized healthcare. Research conducted at GMI focuses on both translational and clinical human genetics and genomic science, meaning discoveries made in the laboratory will advance the field of precision medicine and, ultimately, improve the quality of patient care.

GMI, founded over a decade ago by Charis Eng, MD, PhD, Chairperson, is specifically designed with open laboratory space in order to enhance genomics research. Researchers work together with clinicians in the clinical arm of the Institute — the Center for Personalized Genetic Healthcare — as well as the Genomic Medicine Biorepository, which processes and stores thousands of patient samples and biological molecules linked to a relational database, and the Genomics Core facility, which utilizes cutting-edge genomics technology for multiple researchers within the Cleveland Clinic and externally.

The Institute offers a unique training program to young investigators who wish to apply genomics to their research or medical practice. GMI also coordinates genomic research and practice across many disease areas to enhance interdisciplinary research and healthcare.

 

Symposium Save the Date


NEWS

New Research Collaboration between GMI and CompanionDx™

Charis EngKevin HicksGMI is pleased to announce that Charis Eng, MD, PhD, and Kevin Hicks, PharmD, PhD, will be the national coordinating investigators for UPGRADE (Utility of PharmacoGenomics for Reducing Adverse Drug Effects). UPGRADE is a multicenter registry sponsored by CompanionDx™ that includes up to 279,000 patients enrolled at up to 2,000 clinical sites.

The primary objective is to assess whether pharmacogenomics testing leads to clinically meaningful changes in a patient’s medication regimen.

 “This exemplifies how academic-private partnerships can rapidly achieve meaningful translational research to support the practice of precision medicine,” said Dr. Eng.

 

Pauline Funchain receives Conquer Cancer Foundation Award

Pauline FunchainCongratulations to Pauline Funchain, MD, an Ambrose Monell Clinical Cancer Genomics Fellow in the Eng Lab who received a 2015 Conquer Cancer Foundation ASCO Merit Award. This award recognizes exceptional scientific merit of research conducted by oncology fellows and residents early in their careers, and encourages attendance at the annual American Society of Clinical Oncology (ASCO) Meeting. Pauline attended the Chicago meeting in June to present her abstract titled “Hereditary Implications of Somatic Tumor Testing.”

 

Doctoral Excellence Award in Molecular Medicine goes to Amanda Tilot

Amanda TlotGMI is pleased to announce that Amanda Tilot received the 2015 Doctoral Excellence Award in Molecular Medicine from the Case Western Reserve School of Medicine. This award was established to recognize outstanding graduate students in PhD programs. Successful recipients exhibited exceptional qualities in research, scholarship, service and collaboration.

Amanda earned her PhD in Dr. Charis Eng’s lab, and has accepted a postdoctoral position at the Max Plank Institute for Psycholinguistics in the Netherlands, beginning in May, 2015.

 

2015 Distinguished Service Award to Dr. Charis Eng

Charis Eng in ChicagoDr. Charis Eng, who received her MD and PhD degrees from the University of Chicago, was presented with the 2015 Distinguished Service Award at the Alumni Awards Reception in Chicago. This award, presented by the University of Chicago Biological Sciences Division and the Pritzker School of Medicine, recognizes alumni who have brought honor and distinction to the Division of Biological Sciencesz/Pritzker School of Medicine and to the University of Chicago by demonstrating outstanding leadership in and making significant contributions to the biological sciences or medicine through research, clinical care, health service administration, public and professional service, or civic duties.

 

Ron Rerko shares his views on The Next Milestones for Personalized Medicine

RonRon Rerko, Director, Translational Development, was invited to participate on a panel at the MidAmerica Healthcare Venture Forum held in Chicago in May, 2015. MedCity Media and Mid-America Healthcare Investors Network (MHIN) connected investors with corporate business development executives to highlight investment opportunities with promising start-up companies. The panel examined recent and anticipated innovation in the fields of genomics and personalized medicine, as well as promising areas for investment.

 

 

Cleveland Clinic and Human Longevity combine efforts to study the genetics of heart disease

Description: ttp://www.humanlongevity.com/wp-content/uploads/hli-logo-share.pngThe Genomic Medicine Institute (GMI) and the Center for Clinical Genomics are excited to announce a broad research collaboration with Human Longevity Inc., (HLI), Dr. J. Craig Venter’s company in San Diego, CA. HLI is using genomic sequencing, the human microbiome, proteomics and advanced computing to tackle aging-related human diseases. Under the master agreement negotiated by Dr. Charis Eng, Chairperson, GMI, the initial project is in collaboration with Drs. Wilson Tang and Stan Hazen of the Cleveland Clinic to discover new disease-causing genes and disease pathways associated with heart disease. Read the Story

Dr. Eng notes a great deal of potential moving forward to collect and sequence thousands more samples. “Cleveland Clinic has these precious samples of DNA linked to well-annotated clinical information, and Human Longevity has the firepower with lots of the newest, most cutting-edge sequencers.” Dr. Tang also emphasizes the importance of this joint venture as a major step in building the infrastructure for clinical genomic medicine. “This unique opportunity brings clinicians and researchers from all disciplines to tackle some of the biggest challenges in our daily clinical practices using these powerful yet sophisticated technologies. We are hopeful that this also brings us a step closer to applying these tools at the bedside.”

 

Dr. Charis Eng on 19 Action News

Charis Eng, MD, PhD, Hardis Chair of the Genomic Medicine Institute (GMI) and Director of its clinical arm, the Center for Personalized Genetic Healthcare, was recently interviewed by 19 Action News on the topic of “BRCA Testing: Am I at Risk?”.  Actress Angelina Jolie recently brought this particular genetic screening for breast and/or ovarian cancer to the forefront. After testing positive for a BRCA1 mutation, she chose to have a double mastectomy and eventually had both her ovaries and fallopian tubes removed. The measures she chose were all in the name of being proactive, supported by research evidence, which Dr. Eng feels very strongly about.

Her advice for anyone who is concerned about their risk is to craft an accurate and thorough family health history and speak with a geneticist or genetic counselor. Genetic counselors are trained to help you determine which screenings may benefit you and protect your future health. Dr. Eng believes that too much inappropriate testing of women without the clinical red flags that denote increased inherited risk of cancer is dangerous. She worries that it can yield too many false positive or false negative test results, creating either unnecessary emotional turmoil or unwarranted relief, when there really should be extra attention and care.

“The more we abuse testing in the wrong situation, the more expensive it will be . . . we have to be good stewards of good genetics practice.” In the future, BRCA1 and BRCA2 screening may become a routine part of care once you reach a certain age, but Dr. Eng feels our system is not yet ready for mass testing. In the meantime, taking preventative steps like family health histories and genetic counseling can protect more women from cancer.

 

Congratulations to Brandie Leach on her Appointment as President of the Collaborative Group of the Americas on Inherited Colorectal Cancer!

Description: Brandie Leach, MSWe are proud to announce that Brandie Leach, MS, a Licensed Genetic Counselor in the Center for Personalized Genetic Healthcare (CPGH), the clinical arm of the Genomic Medicine Institute, was elected President of the Collaborative Group of the Americas on Inherited Colorectal Cancer. This group aims to advance research on several rare forms of inherited colorectal cancers, as well as improve clinical care for patients and families affected by these diseases.

Ms. Leach specializes in cancer genetic counseling and this appointment marks the first time a genetic counselor has been elected President of this group. Genetic counselors are healthcare professionals with specialized training in medical genetics and counseling.

 

GMI Team Joins Together to Make LRI "Science Day" a Success

Angela Ting, PhD, a Principal Investigator in the GMI, led the Lerner Research Institute’s (LRI) second annual “LRI Science Day” for students from Citizens Leadership Academy (CLA), a local charter school. Students in grades 6-8 were asked to submit a contest entry in the form of an essay, drawing, poem or photograph about their interest in science and medicine. From this competition, 50 students were invited to attend.

Fellow GMI personnel also took an active role in this popular event. David Serre, PhD, spoke on his beginnings in science and the state of the Cuyahoga River, while Jessica Mester, MS, Licensed Genetic Counselor, spoke to a group on genetic inheritance. Competitive DNA extraction was also performed by research technologists Todd Romigh, MS, and Sirena Meade, MS and PhD candidate Lamis Yehia, MS.

GMI is proud to be a part of this outreach program, which encourages students from underprivileged backgrounds to pursue a career in science, while raising awareness in our surrounding communities of the diverse and exciting research going on in LRI and CCF. Dr. Ting explains that many scientists and physicians say they became intrigued by science at an early age, and she hopes this program will foster that interest in young children. “Different kids are fascinated by different things – we try to give them a broad, hands-on experience, and we hope to connect with them.”


Genomics Core awarded NIH Shared Instrumentation Grant

Genomics Core awarded NIH Shared Instrumentation Grant  The Lerner Research Institute’s Genomics Core, under the scientific direction of Charis Eng, MD, PhD, has been awarded a $600,000 NIH Shared Instrumentation Grant (Dr. Eng is the PI on the grant) to significantly upgrade its next generation sequencing capabilities.

Read more...


Germline PTEN Mutations Raise Second Cancer Risk

Germline PTEN Mutations Raise Second Cancer Risk Charis Eng, MD, PhD, Genomic Medicine Institute Chair, recently published a paper in the Journal of Clinical Oncology entitled “Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations.”

Read more...


Micheala Aldred, PhD presented at the 2014 American Thoracic Society’s International Conference

Micheala Aldred, PhD presented at the 2014 American Thoracic Society’s International Conference Micheala Aldred, PhD, Genomic Medicine Institute, was invited to be the “featured speaker” and conclude the session on Epigenetics in Pulmonary Hypertension: Novel Mechanisms and Targets at the 2014 American Thoracic Society Conference. Dr. Aldred’s presentation was entitled “Epigenetics: A changeable landscape.”

Read more...


Congratulations to Amanda Tilot (Eng Lab) on winning the F. Merlin Bumpus Junior Investigator Award!

Amanda Tilot (Eng Lab) on winning the F. Merlin Bumpus Junior Investigator Award Amanda Tilot, doctoral student in the Molecular Medicine program, was named the winner of the F. Merlin Bumpus Junior Investigator Award. This award highlights excellence in research by graduate students and postdoctoral fellows in both basic science and clinical areas.

Read more...


Charis Eng, MD, PhD and Angela Ting, PhD presented at the Friends of the LRI Seminar Series

Charis Eng, MD, PhD and Angela Ting, PhD presented at the Friends of the LRI Seminar Series The Friends of the LRI event highlights discoveries and innovations in treating specific disease areas and provides a unique opportunity to engage one-on-one with some of the world’s leading scientists.

Read more...


Fox 8 News Interviews Charis Eng, MD, PhD and Thomas Frazier II, PhD regarding Autism-related Research Efforts

Fox 8 News Interviews Charis Eng, MD, PhD and Thomas Frazier II, PhD regarding  Autism-related  Research Efforts Charis Eng, MD, PhD, Chair of the Cleveland Clinic’s Genomic Medicine Institute and Thomas Frazier II, PHD, Director of the Children’s Hospital Center for Autism are working to investigate autism and genetic related factors. Dr. Eng has discovered a gene mutation that predisposes people to certain kinds of cancer that can also be linked with autism. To learn more about this exciting research, watch interview here.


Charis Eng, MD, PhD. - Rising To The Top and Helping Others Along The Way

Charis Eng, MD, PhD. - Rising To The Top and Helping Others Along The Way Dr. Charis Eng has achieved much during her busy life. Being a woman in the field of medicine and medical research has not always been easy, especially when it comes to being mentored.

Read more...


Charis Eng, M.D., Ph.D. delivers the 17th Annual Charlotte Friend Memorial Lectureship

Charis Eng, M.D., Ph.D. delivers the 17th Annual Charlotte Friend Memorial Lectureship The American Association for Cancer Research awarded Dr. Charis Eng with the Women in Cancer Research Charlotte Friend Memorial Lectureship. She was the 17th annual award recipient. The lecture is intended to give recognition to an outstanding female or male scientist who has made meritorious contributions to the field of cancer research along with furthering the advancement of women in science through leadership or by example. Dr. Eng gave this lecture at the 2014 AACR Annual Meeting in San Diego, CA.

Read more...

The American Medical Women’s Association’s awards Charis Eng, MD, PhD with the Exceptional Mentor Award.

The American Medical Women’s Association’s awards Charis Eng, MD, PhD with the Exceptional Mentor Award. Charis Eng, MD, PhD, Chair of GMI, recently received the American Medical Women’s Association’s Exceptional Mentor award. The American Medical Women’s Association (AMWA) is an organization of women physicians, medical students and other persons dedicated to serving as the unique voice for women’s health and the advancement of women in medicine.

Dr. Eng was anonymously nominated by a past mentee. This award acknowledges mentors who have selflessly contributed to the professional development and growth of women in medicine. Dr. Eng was honored at an awards luncheon in Washington, DC.

Read more...

Leading the Way in Biomedical Research…

Leading the Way in Biomedical ResearchThe European Journal of Clinical Investigation named Charis Eng, MD, PhD, Chair, Lerner Research Institute’s Genomic Medicine Institute, and Jeffrey Cummings, MD, Director, Lou Ruvo Center for Brain Health, among the world’s most highly influential biomedical researchers. The article recognizes 407 biomedical researchers from around the world based on Scopus publication impact and citation data from 1996–2011.

Read more...


The Genomic Medicine Institute hosts the Charles R. Drew Saturday Academy

The Genomic Medicine Institute hosts the Charles R. Drew Saturday AcademyThe Genomic Medicine Institute (GMI) hosted the Charles R. Drew Saturday Academy high school students on February 1, 2014. This is the fourth consecutive year GMI’s researchers, clinicians, and laboratory technicians teamed up to provide a tour of GMI and an overview of GMI’s work in the areas of genomic research, patient care, and public education. 

Read more...


Kylie Drake Wins Two Awards to Advance PAH Research

Dr. Drake Receiving Gilead Sciences Research Scholar AwardCongratulations to Kylie Drake, PhD, for being awarded a Gilead Sciences Research Scholarship AND a Proof-of-Concept grant from the Pulmonary Hypertension Association.

Read more...







Whole Genomic Sequencing of the Plasmodium vivax Malaria Parasite

Mosquito & ChloroquineThe Genomic Medicine Institute is collaborating with Case Western Reserve University, the Institut Pasteur du Cambodge and other geographically dispersed institutions to combat the spread of malaria. Genetic sequencing of the Plasmodium vivax malaria parasite, conducted by David Serre’s lab, sheds light on its mechanism of infecting humans. This research may prove critical for heading off the rapid spread of anadapted form of malaria throughout Africa.

Read more…



Ting LabAngela Ting, PhD Awarded Grant to Study Epigenetic Mechanisms in Colon Cancer

Angela Ting, PhD, Assistant Staff in the Genomic Medicine Institute, has been awarded a grant from the Case Comprehensive Cancer Center. Her research, entitled “Functional Delineation of Abnormal 3’ DNA Methylation in Colon Cancer,” will improve our mechanistic understanding of colon cancer development and progression. Read more...


Ting Laboratory, from left: Angela Ting, PhD, Nagarajavel Vivekananthan, PhD, and Thomas Sweet, PhD


Dr. Charis Eng Featured in New York Times

Research connecting autism with the PTEN genetic mutation was recently featured in the New York Times Health section. “Autism’s Unexpected Link to Cancer Gene,” published on August 11th, highlighted recent research conducted by Charis Eng, MD, PhD, Chair of the Genomic Medicine Institute, in collaboration with Thomas Frazier, MD, Director of the Cleveland Clinic’s Center for Autism. Read the full story. (New York Times subscription required.)

 

Developing Comprehensive Guidelines for Identifying and Managing Patients with PTEN Mutations

Charis Eng, MD, PhDMany people with Cowden Syndrome, Bannayan-Riley-Ruvalcaba Syndrome, and a few other genetic conditions have been found to have PTEN gene mutations as the cause of their medical concerns. The reseearch team led by Charis Eng, MD, PhD, developed a semi-quantitative score—the Cleveland Clinic (CC) score—that relates the prevalence of clinically observed symptoms in adults to the probability of harboring a PTEN mutation.

Read more...